Skip to main content
Equibles

TCG Crossover Management, LLC

Position in LBRX — Lb Pharmaceuticals Inc

CIK 1839948 PALO ALTO, CA
Back to LBRX Full portfolio

Position in LBRX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$46,972,446
+$1,610,648 QoQ
Shares Held
1,447,310
-21.3% QoQ
Ownership
4.49%
of shares outstanding
% of Portfolio
1.13%
of 13F equity value
Holder Rank
#7
of 115 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in LBRX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

TCG Crossover Management, LLC holds $3,891,479,135 across 48 Biotechnology names. LBRX ranks #22 (1.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ABVX
Abivax S.A.
 6,007,834 $800,603,958
2 TNGX
Tango Therapeutics, Inc.
 9,081,201 $283,878,343
3 CGON
CG Oncology, Inc.
 3,670,206 $260,768,136
4 COGT
Cogent Biosciences, Inc.
 4,854,436 $187,866,673
5 IMVT
Immunovant, Inc.
 4,457,988 $171,766,277
6 SYRE
Spyre Therapeutics, Inc.
 1,900,582 $168,733,669
7 DNTH
Dianthus Therapeutics, Inc. /DE/
 1,676,624 $163,437,307
8 MIRM
Mirum Pharmaceuticals, Inc.
 1,062,049 $124,334,076

All Filings in LBRX

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $46,972,446 1,447,310
2026-03-31 $45,361,798 1,839,489
2025-12-31 $38,844,033 1,745,015
2025-09-30 $27,553,802 1,745,016